Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Inflammatory Bowel Diseases

Free Subscription 30.05.2022 3 Aliment Pharmacol Ther 1 Am J Gastroenterol 2 BMC Gastroenterol 1 BMJ 1 Dis Colon Rectum 2 Gastroenterol Hepatol 1 Gut 1 J Crohns Colitis 1 PLoS One 1 Scand J Gastroenterol

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Aliment Pharmacol Ther

1. ROSIOU K, Carbonell J, Dolby V, Monfared N, et al
   Sources of excess steroid prescriptions and clinical adverse outcomes associated with steroid excess in patients with inflammatory bowel disease: The Leeds IBD Steroids study.
   Aliment Pharmacol Ther. 2022 May 24. doi: 10.1111/apt.17039.
   PubMed         Abstract available
   
   
2. DRUVEFORS E, Andersson RE, Hammar U, Landerholm K, et al
   Minor impact on fertility in men with inflammatory bowel disease: A National Cohort Study from Sweden.
   Aliment Pharmacol Ther. 2022 May 22. doi: 10.1111/apt.16984.
   PubMed         Abstract available
   
   
3. QUINN KP, Busciglio IA, Burton DD, Inoue A, et al
   Defining normal pouch function in patients with ileal pouch-anal anastomosis: a pilot study.
   Aliment Pharmacol Ther. 2022;55:1560-1568.
   PubMed         Abstract available
   
   

   
   Am J Gastroenterol

4. MARILD K, Soderling J, Lebwohl B, Green PH, et al
   ASSOCIATION OF CELIAC DISEASE AND INFLAMMATORY BOWEL DISEASE: A NATIONWIDE REGISTER-BASED COHORT STUDY.
   Am J Gastroenterol. 2022 May 25. pii: 00000434-990000000-00380.
   PubMed         Abstract available
   
   

   
   BMC Gastroenterol

5. LOGAN M, MacKinder M, Clark CM, Kountouri A, et al
   Intestinal fatty acid binding protein is a disease biomarker in paediatric coeliac disease and Crohn's disease.
   BMC Gastroenterol. 2022;22:260.
   PubMed         Abstract available
   
   
6. LARSEN PT, Jorgensen SF, Njor SH
   Colorectal cancer screening participation among citizens not recommended to be screened: a cohort study.
   BMC Gastroenterol. 2022;22:256.
   PubMed         Abstract available
   
   

   
   BMJ

7. SAUL H, Gursul D, Lyratzopoulos G
   When do people with abdominal symptoms need a fast track referral?
   BMJ. 2022;377:o1198.
   PubMed         Abstract available
   
   

   
   Dis Colon Rectum

8. DAGBERT F, Richard CS
   Restorative Proctocolectomy for Ulcerative Colitis: Different Strategies for Different Situations.
   Dis Colon Rectum. 2022 May 25. pii: 00003453-990000000-00055.
   PubMed        
   
   

   
   Gastroenterol Hepatol

9. ROIG CA, Ferrer CS, Garcia JLR, Cordon JP, et al
   "Influence of biologic therapy on cardiovascular risk factors in patients with inflammatory bowel disease".
   Gastroenterol Hepatol. 2022 May 20. pii: S0210-5705(22)00156.
   PubMed         Abstract available
   
   
10. ALGABA A, Romero S, Granja A, Garza D, et al
    Serological Response To Vaccines Against Sars-Cov-2 In Patients With Inflammatory Bowel Disease.
    Gastroenterol Hepatol. 2022 May 20. pii: S0210-5705(22)00154.
    PubMed         Abstract available
    
    

    
    Gut

11. QUAN J, Ma C, Panaccione R, Hracs L, et al
    Serological responses to three doses of SARS-CoV-2 vaccination in inflammatory bowel disease.
    Gut. 2022 May 23. pii: gutjnl-2022-327440. doi: 10.1136/gutjnl-2022-327440.
    PubMed        
    
    

    
    J Crohns Colitis

12. TORRENTE F, Meade S, Benchimol EI, de Ridder L, et al
    Thromboprophylaxis use in paediatric inflammatory bowel disease: an international RAND appropriateness panel.
    J Crohns Colitis. 2022 May 24. pii: 6591364. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    PLoS One

13. SHEU NW, Huang SH, Wu DC, Kao JY, et al
    Effects of Helicobacter pylori treatment on the incidences of autoimmune diseases and inflammatory bowel disease in patients with diabetes mellitus.
    PLoS One. 2022;17:e0265323.
    PubMed         Abstract available
    
    

    
    Scand J Gastroenterol

14. FERNANDES SR, Rodrigues IC, Serrazina J, Botto IA, et al
    Proactive infliximab is more effective than vedolizumab in inducing fecal calprotectin remission in inflammatory bowel disease.
    Scand J Gastroenterol. 2022 May 22:1-7. doi: 10.1080/00365521.2022.2076567.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Inflammatory Bowel Diseases is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: